Evogene Ltd.
EVGNNASDAQHealthcare● Active
$0.58
$-0.04(-5.82%)
Market Cap$5023607
P/E Ratio—
52W High$2.42
52W Low$0.52
Evogene Ltd. (EVGN) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · EVGN · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $3.85M | $5.58M | $2.98M | $1.68M | $0.93M |
| Cost of Revenue | $4.09M | $2.38M | $1.49M | $0.91M | $0.77M |
| Gross Profit | ($0.24M) | $3.20M | $1.49M | $0.77M | $0.16M |
| Gross Margin %(computed) | -6.25% | 57.32% | 50.03% | 45.73% | 17.53% |
| Operating Expenses | |||||
| R&D Expenses | $7.99M | $12.51M | $16.20M | $20.79M | $21.13M |
| G&A Expenses | $5.58M | $8.75M | $7.37M | $10.28M | $9.34M |
| Total Operating Expenses | $13.79M | $22.00M | $23.72M | $27.71M | $31.12M |
| Operating Income | ($14.03M) | ($18.80M) | ($22.23M) | ($26.94M) | ($30.95M) |
| Operating Margin %(computed) | -364.24% | -337.17% | -745.51% | — | — |
| Interest Income | $2.47M | $0.96M | $1.25M | $0.18M | $0.29M |
| Interest Expense | $1.89M | $0.12M | $0.17M | $0.24M | $0.40M |
| Income Before Tax | ($13.50M) | ($14.81M) | ($21.95M) | ($29.75M) | ($30.43M) |
| Income Tax Expense | $0.00M | $0.01M | $0.02M | $0.09M | $0.01M |
| Net Income | ($8.48M) | ($16.48M) | ($23.88M) | ($26.64M) | ($27.79M) |
| Net Margin %(computed) | -220.22% | -295.59% | -800.77% | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.08 | $-2.89 | $-5.23 | $-6.46 | $-0.68 |
| Wtd Avg Shares | 7.87M | 5.70M | 4.57M | 4.12M | 41.01M |
| EBITDA | ($12.20M) | ($13.36M) | ($20.53M) | ($27.01M) | ($27.88M) |
| EBITDA Margin %(computed) | -316.56% | -239.63% | -688.53% | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Evogene Ltd. data
About Evogene Ltd. (EVGN) Income Statement
Evogene Ltd. (EVGN) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, EVGN reported revenue of $0.00B, gross profit of ($0.00B) (gross margin -6.25%), and net income of ($0.01B) — a net profit margin of -220.22%.
Frequently asked questions
EVGN · 4 questionsEvogene Ltd. (EVGN) reported revenue of $0.00B for 2025, down 30.9% year-over-year.
EVGN revenueEVGN salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08